Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of zasocitinib in active psoriatic arthritis stratified by prior biologic use
CTR20251181Phase 3Active
- Sponsor
- Takeda
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of zasocitinib in psoriatic arthritis (PsA), sponsored by Takeda. Started Jun 2025; status: active.
02
Drugs
zasocitinib
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on CTR20251181.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251181.